Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

E-GEOD-27887

ABSTRACT: Transcription profiling by array of skin from patients with atopic dermatitis before and after treatment with narrow-band UVB radiation

OTHER RELATED OMICS DATASETS IN: PRJNA138001

PROVIDER: E-GEOD-27887 | ExpressionAtlas | 2025-01-24

REPOSITORIES: ExpressionAtlas

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	E-GEOD-27887-analysis-methods.tsv	Tabular
	E-GEOD-27887-atlasExperimentSummary.Rdata	Rdata
	E-GEOD-27887-configuration.xml	Xml
	E-GEOD-27887-percentile-ranks.tsv	Tabular
	E-GEOD-27887.condensed-sdrf.tsv	Tabular

Items per page:

1 - 5 of 87

Similar Datasets

E-GEOD-58558

Project description:Transcription profiling of skin samples from atopic dermatitis patients before and after treatment with cyclosporine A

2025-01-24 | E-GEOD-58558 | ExpressionAtlas

E-GEOD-59294

Project description:Transcription profiling of skin from patients with moderate to severe atopic dermatitis before and after treatment with IL-4R inhibitor dupilumab (REGN668/SAR231893)

2025-01-24 | E-GEOD-59294 | ExpressionAtlas

Transcription profiling by array of skin from patients with atopic dermatitis before and after treatment with narrow-band UVB radiation

Project description:Background: Atopic dermatitis (AD) is a common inflammatory skin disease exhibiting a predominantly Th2/"T22" immune activation and a defective epidermal barrier. Narrow-band UVB (NB-UVB) is considered an efficient treatment for moderate to severe AD. In psoriasis, NB-UVB has been found to suppress the Th1/Th17 immune polarization with subsequent reversal of epidermal hyperplasia. The immunomodulatory effects of this treatment are largely unknown in AD. Our study evaluates the effects of NB-UVB on immune and barrier abnormalities in AD, aiming to establish reversibility of disease and biomarkers of therapeutic response. Methods: 12 moderate-to-severe chronic AD patients received NB-UVB phototherapy 3 times weekly for up to 12 weeks. Lesional and non-lesional skin biopsies were obtained before and after treatment and evaluated by gene-expression and immunohistochemistry studies. Results: All patients had at least a 50% reduction in SCORing of AD (SCORAD) index with NB-UVB phototherapy. The Th2, T22, and Th1 immune pathways were suppressed and measures of epidermal hyperplasia and differentiation also normalized after phototherapy. The reversal of disease activity was associated with elimination of inflammatory leukocytes, Th2/"T22"-associated cytokines and chemokines, and normalized expression of barrier proteins. Conclusions: Our study shows reversal of both the epidermal defects and underlying immune activation in AD. By determining the correlation of variables with therapeutic response, we have defined a set of biomarkers of disease response that associate resolved Th2 and T22 inflammation with reversal of barrier pathology. This data supports the "inside-out" hypothesis of AD, suggesting that it is a disease primarily driven by an immune stimulus. genomic profiling of treatment effect of NB-UVB in AD in both lesional and non-lesional AD skin from 10 patients. Treatment effect, disease state analysis

2011-07-01 | E-GEOD-27887 | biostudies-arrayexpress

Gene expression changes in atopic dermatitis after treatment with nb-UVB

Project description:Background: Atopic dermatitis (AD) is a common inflammatory skin disease with broad impact on quality of life and on the health care system. The pathophysiology is not fully understood, but it is likely multifactorial involving immune dysfunction, altered skin barrier and environmental factors. Narrow band ultraviolet B (nb-UVB) treatment leads to normalization of the tissue and clinical improvement. However, knowledge of early changes in AD skin in response to nb-UVB is lacking and could provide important clues to decipher the disease mechanisms and potential new treatment targets. Objective: To map the early transcriptional changes in the skin in response to nb-UVB treatment. Results: When examining the early response after only three local UVB-treatments, gene expression analysis revealed 30 down- and 47 up-regulated transcripts. Among these only a small proportion were related to the inflammatory response. Interestingly, two cytokines of the interleukin (IL)-1 family were differentially expressed: the proinflammatory cytokine IL-36γ was reduced after treatment, while the anti-inflammatory cytokine IL-37 increased in skin after treatment with nb-UVB. Conclusion: Local nb-UVB induced an early decrease of the pro-inflammatory cytokine IL-36γ and an increase of the anti-inflammatory IL-37. This likely represents one of the first changes in inflammatory signaling induced by nb-UVB in atopic eczema.

2020-10-27 | GSE150797 | GEO

Reversal of Atopic Dermatitis with Narrow-Band UVB Phototherapy and Biomarkers for Therapeutic Response

Project description:Background: Atopic dermatitis (AD) is a common inflammatory skin disease exhibiting a predominantly Th2/“T22” immune activation and a defective epidermal barrier. Narrow-band UVB (NB-UVB) is considered an efficient treatment for moderate to severe AD. In psoriasis, NB-UVB has been found to suppress the Th1/Th17 immune polarization with subsequent reversal of epidermal hyperplasia. The immunomodulatory effects of this treatment are largely unknown in AD. Our study evaluates the effects of NB-UVB on immune and barrier abnormalities in AD, aiming to establish reversibility of disease and biomarkers of therapeutic response. Methods: 12 moderate-to-severe chronic AD patients received NB-UVB phototherapy 3 times weekly for up to 12 weeks. Lesional and non-lesional skin biopsies were obtained before and after treatment and evaluated by gene-expression and immunohistochemistry studies. Results: All patients had at least a 50% reduction in SCORing of AD (SCORAD) index with NB-UVB phototherapy. The Th2, T22, and Th1 immune pathways were suppressed and measures of epidermal hyperplasia and differentiation also normalized after phototherapy. The reversal of disease activity was associated with elimination of inflammatory leukocytes, Th2/“T22”-associated cytokines and chemokines, and normalized expression of barrier proteins. Conclusions: Our study shows reversal of both the epidermal defects and underlying immune activation in AD. By determining the correlation of variables with therapeutic response, we have defined a set of biomarkers of disease response that associate resolved Th2 and T22 inflammation with reversal of barrier pathology. This data supports the “inside-out” hypothesis of AD, suggesting that it is a disease primarily driven by an immune stimulus.

2011-07-01 | GSE27887 | GEO

E-GEOD-32924

Project description:Transcription profiling by array of lesional and non-lesional skin from atopic dermatitis patients and healthy individuals

2025-01-24 | E-GEOD-32924 | ExpressionAtlas

Gene Profiling of Narrow-band UVB-induced Skin Injury Defines Cellular and Molecular Innate Immune Responses

Project description:We sought to define the cutaneous response at 24 hours following erythemogenic doses of narrow-band UVB (NB-UVB, 312 nm peak) exposure and determine the differences between irradiated and non-irradiated skin. Comparison of Transcriptome between NB-UVB irradiated (2MED) and non-irradiated skin (NON IRRAD).

2012-10-30 | E-GEOD-41078 | biostudies-arrayexpress

Gene Profiling of Narrow-band UVB-induced Skin Injury Defines Cellular and Molecular Innate Immune Responses

2012-10-30 | GSE41078 | GEO

Homo sapiens

Project description:Reversal of Atopic Dermatitis with Narrow-Band UVB Phototherapy and Biomarkers for Therapeutic Response

| PRJNA138001 | ENA

E-GEOD-36842

Project description:Transcription profiling by array of acute and chronic atopic dermatitis compared to normal skin

2025-01-24 | E-GEOD-36842 | ExpressionAtlas